Jacobs Solutions (NYSE:J) 株価情報

JACOBS SOLUTIONS INC

Jacobs Solutions

Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.

Jacobs Engineering Group

Jacobs Solutions Inc

Janus Henderson AAA CLO ETF

JAC JAPAN CO LTD ORD by Jac Japan Co., Ltd.

JAC Recruitment Co Ltd

Jack In The Box Inc

JACO ELECTRONICS INC by JACO Electronics, Inc.

Jaco Electronics Inc

Jackson Acquisition Company II Class A Ordinary Shares

Jackson Acquisition Co II

Jackson Acquisition Company II Units, each consisting of one Class A ordinary share and one right to acquire one-tenth (1/10) of one Class A ordinary share

JACCS CO by Jaccs Co.

Jackson Acquisition Company II Rights, each right to acquire one-tenth (1/10) of one Class A ordinary share

JADE ART GROUP INC by Jade Art Group, Inc.

Jade Art Group Inc

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Developing Markets Equity ETF

Jaguar Mining Inc

JAAG ENTERPRISES LTD. by JAAG Enterprises Ltd.

JAAG Enterprises Ltd

GREEN STREET CAPITAL CORP by Green Street Capital Corp

Green Street Capital Corp

Jaguar Health Inc

JUSTIN ALLEN HLDGS LTD by JUSTIN ALLEN HLDGS LTD.

JAPAN AIRPORT TERMINAL by Japan Airport Terminal

Japan Airport Terminal Co Ltd

JAJ DISTRIBUTION SA by JAJ DISTRIBUTION SA

Innovator Equity Defined Protection ETF - 6 Mo Jan/Jul

Jakks Pacific Inc

JAKKS PACIFIC 6% PFD A by JAKKS Pacific, Inc.

ADAMS (JOHN) LIFE CORP by Adams (JOHN) Life Corp.

John Adams Life Corp

Jamf Holding Corp

Tuktu Resources Ltd

Jammin Java Corp

Innovator ETFs Trust Premium Income 10 Barrier ETF January

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - January

Janel Corp

First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - January

PGIM S&P 500 Buffer 12 ETF - January

Innovator ETFs Trust US Equity Prem Income 40 Barrier ETF - January

AllianzIM U.S. Large Cap Buffer10 Jan ETF

AIM ETF Products Trust AllianzIM U.S. Equity Buffer15 Uncapped Jan ETF

AllianzIM U.S. Large Cap Buffer20 Jan ETF

Janux Therapeutics Inc

TrueShares Structured Outcome (January) ETF

Japan Tobacco Inc

Horizon Kinetics Japan Owner Operator ETF

JAPAN SYS TECHNIQUES CO by Japan Systems Techniques Co. Ltd.

Japan System Techniques Co Ltd

JAPAN AIRLINES UNSP/ADR by Japan Airlines Ltd

Japan Airlines Co Ltd

Jupiter Acquisition Corp

Jupiter Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Jupiter Acquisition Corp Warrants (04/09/2025)

JARDINE MATHESON HLDG ORD by Jardine Matheson Holdings Ltd.

Jardine Matheson Holdings Ltd

JasmyCoin - United States Dollar

JASTEC Co Ltd

JASMINE INTL PLC NVDR by Jasmine International Public Co., Ltd.

Jasmine International PCL

JAPAN TRANSCITY CORP ORD by Japan Transcity Corp.

Japan Transcity Corp

JPMorgan Active Value ETF

Vinyl Group Ltd

PT JAYA KONSTRUKSI NEW by PT Jaya Konstruksi Manggala Pratama TBK

PT Jaya Konstruksi Manggala Pratama Tbk

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

JULIUS BAER GRUPPE NAMEN by Julius Baer Group Ltd.

Julius Baer Gruppe AG

JULIUS BAER GRP UNSP/ADR by Julius Baer Group Ltd.

Janus Detroit Street Trust Janus Henderson B-BBB CLO ETF

JBDI Holdings Ltd

JOLLIBEE FOODS CORP by Jollibee Foods Corp.

Jollibee Foods Corp

JOLLIBEE FOODS UNSP/ADR by Jollibee Foods Corp.

JBG SMITH Properties

JB HI-FI LTD UNSP/ADR by JB Hi-Fi Limited

JB Hi Fi Ltd

J.B. Hunt Transport Services, Inc. - Common Stock

JB Hunt Transport Services Inc

Janus International Group, Inc. Common Stock

Janus International Group Inc

JUMBO INTERACTIVE LTD by JUMBO INTERACTIVE LTD.

Jumbo Interactive Ltd

Jade Biosciences Inc

Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I

Jabil Inc

JetBlue Airways Corporation - Common Stock

JetBlue Airways Corp

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Bond ETF

SWISSCANTO ETF PREC METLS by Julius Baer Precious Metals

JACOBIO PHARMACEUTICALS by Jacobio Pharmaceuticals Group Co Ltd.

Jacobio Pharmaceuticals Group Co Ltd

JBS SA

John B. Sanfilippo & Son, Inc. - Common Stock

John B Sanfilippo & Son Inc

Jbt Bancorp Inc

JBT Marel Corp

JAMES BAY MINERALS LTD by JAMES BAY MINERALS LTD

JB&ZJMY HOLDING CO by JB&ZJMY Holding Company, Inc.

JB&ZJMY Holding Co Inc

JCDecaux SE

Nuveen Core Equity Alpha Fund Common Shares of Beneficial Interest

Nuveen Core Equity Alpha Fund

JPMORGAN CHINESE INV TR by JPMorgan Chinese Investment Trust PLC

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active China ETF

Johnson Controls International plc Ordinary Share

Johnson Controls International PLC

JPMorgan Core Plus Bond ETF

J P MORGAN EXCHANGE-TRADED FD TR JPMorgan Inflation Managed Bond ETF

JCR PHARMACEUTICALS CO by JCR PHARMACEUTICALS CO LTD.

JCR Pharmaceuticals Co Ltd

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Holdings Ltd

Jewett-Cameron Trading Company - Common Shares

Jewett-Cameron Trading Co Ltd

JPMorgan Carbon Transition U.S. Equity ETF

JARDINE CYCLE&CARRAGE LTD by Jardine Cycle & Carriage Limited

Jardine Cycle & Carriage Ltd

JARDINE CYCL&CARRGE U/ADR by Jardine Cycle & Carriage Limited

JD.com, Inc. - American Depositary Shares

JD.com Inc

JUDO CAP HLDGS LTD by JUDO CAP HLDGS LTD.

Judo Capital Holdings Ltd

JD SPORTS FASHION PLC NEW by JD Sports Fashion PLC

JD Sports Fashion PLC

Boston Omaha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOC#NYSE">BOC</a>) reported quarterly losses of $(0.02) per share. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $27.73 million which beat the analyst consensus estimate of $27.10 million by 2.32 percent. This is a 8.52 percent increase over sales of $25.55 million the same period last year.

Earnings

Earnings Beats

News

Boston Omaha Q1 EPS $(0.02) Up From $(0.09) YoY, Sales $27.73M Beat $27.10M Estimate

Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.08) by 125 percent. This is a 80 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.34 million which beat the analyst consensus estimate of $500.00 thousand by 168.20 percent. This is a 25.92 percent increase over sales of $1.06 million the same period last year.

Earnings Misses

PGEN

Precigen Q1 EPS $(0.18) Misses $(0.08) Estimate, Sales $1.34M Beat $500.00K Estimate

Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) reported $17.39 million in sales this quarter.

ALMS

Alumis Q1 Sales $17.39M

WIIM

Graphjet Technology shares are trading higher after the company disclosed in 13D filing that its Co-Founder, CEO and CFO Aiden Lee Ping Wei reported A 48.9% stake in the company.

Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.66) by 22.73 percent. This is a 30.14 percent increase over losses of $(0.73) per share from the same period last year.

ACRV

Acrivon Therapeutics Q1 EPS $(0.51) Beats $(0.66) Estimate

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.05) per share. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $41.56 million in sales this quarter. This is a 8.55 percent decrease over sales of $45.45 million the same period last year.

Harte-Hanks Q1 Adj. EPS $(0.05) Down From $(0.02) YoY, Sales $41.56M Down From $45.45M YoY

Insider Trades

Co-Founder, CEO And CFO Aiden Lee Ping Wei Reports 48.9% Stake In Graphjet Technology

Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported $29.51 million in sales this quarter. This is a 17.00 percent decrease over sales of $35.55 million the same period last year.

SYPR

Sypris Solutions Q1 EPS $(0.04) Up From $(0.10) YoY, Sales $29.51M Down From $35.55M YoY

Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the same period last year.

ANRO

Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) reported financial results for the first quarter after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45419679/coreweave-reports-strong-first-quarter-2025-results">of the report</a>.
Q1 Earnings: CoreWeave reported first-quarter revenue of $981.63 million, beating analyst <a href="http://benzinga.com/quote/crwv/earnings">estimates</a> of $859.77 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of $1.49 per share.
Total revenue was up 420% on a year-over-year basis. The company said it ended the quarter with a revenue backlog of $25.9 billion. CoreWeave noted that a strategic deal with OpenAI during the quarter added $11.2 billion in revenue backlog. 
The company reported $1.01 billion in operating expenses during the period, up 487% year-over-year, and ended the quarter with $1.28 billion in cash and cash equivalents. 
&#8220;We&#8217;ve delivered an outstanding start to 2025 on multiple fronts. Our strong&nbsp;first quarter&nbsp;financial performance caps a string of milestones including our IPO, our major strategic deal with OpenAI as well as other customer wins, our acquisition of Weights &amp; Biases and many technical achievements,&#8221; said Michael Intrator, co-founder and CEO of CoreWeave.
&#8220;Demand for our platform is robust and accelerating as AI leaders seek the highly performant AI cloud infrastructure required for the most advanced applications. We are scaling as fast as possible to capture that demand. The future runs on CoreWeave.&#8221;
CoreWeave executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET. The company noted that it will provide forward guidance on the call.
CoreWeave has operated data centers across the U.S. and&nbsp;Europe since 2017. The company provides access to Nvidia GPUs to large technology and AI-focused companies.&nbsp;CoreWeave made its public debut on the Nasdaq at $40 per share in March.
CRWV Price Action: <a href="http://benzinga.com/quote/crwv">CoreWeave shares</a> were trading at all-time highs heading into Wednesday&#8217;s report, its first as a public company. The stock was up 7.92% at $68.97, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a></li>
</ul>
Photo: Shutterstock.

Guidance

Movers

Tech

CRWV

Nvidia-Backed CoreWeave Reports Q1 Earnings: Revenue Jumps 420%, Backlog Grows To $25.9 Billion Following OpenAI Deal, Shares Hit All-Time Highs

CoreWeave shares are trading higher following Q1 financial results.

Inhibrx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) reported quarterly losses of $(2.80) per share which beat the analyst consensus estimate of $(2.84) by 1.41 percent. This is a 51.47 percent increase over losses of $(5.77) per share from the same period last year.

INBX

Inhibrx Q1 EPS $(2.80) Beats $(2.84) Estimate

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $491.00 thousand which missed the analyst consensus estimate of $1.38 million by 64.42 percent. This is a 49.17 percent decrease over sales of $966.00 thousand the same period last year.

ARMP

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for FY2026 Adj EPS of $2.75-$3.25 vs $3.41 analyst estimate. sees sales of $12.180 billion-$12.440 billion vs $12.41 billion analyst estimate.

DXC Technology Sees FY2026 Adj EPS $2.75-$3.25 vs $3.41 Est; Sees Sales $12.180B-$12.440B vs $12.41B Est

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for Q1 Adj EPS of $0.55-$0.65 vs $0.77 analyst estimate. sees sales of $3.040 billion-$3.090 billion vs $3.12 billion analyst estimate.

DXC Technology Sees Q1 Adj EPS $0.55-$0.65 vs $0.77 Est; Sees Sales $3.040B-$3.090B vs $3.12B Est

SPACE

General

RKLB

NASA Selects Rocket Lab To Launch Aspera Mission To Study Galaxy Evolution

Okeanis Eco Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECO#NYSE">ECO</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.24 by 50 percent. This is a 70.73 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $80.15 million which beat the analyst consensus estimate of $74.56 million by 7.49 percent. This is a 27.95 percent decrease over sales of $111.23 million the same period last year.

Okeanis Eco Tankers Q1 Adj. EPS $0.36 Beats $0.24 Estimate, Sales $80.15M Beat $74.56M Estimate

CSCO

Cisco Says EPS Guidance Includes Estimated Impact Of Tariffs Based On Current Trade Policy; AI Infrastructure Orders Surpassing Our $1B Target One Quarter Early

GEE Group Q2 Adj. EPS $(0.30), Sales $24.50M Down From $28.05M YoY

Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.

Comments

Jacobs Solutions

ニュース

パートナーシップ

ベンジンガ・グローバル